Eton Pharmaceuticals Inc. (ETON) Misses Q4 EPS by 5c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of ($0.09), $0.05 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.7 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance